Biphenyl compounds useful as muscarinic receptor antagonists
This invention provides compounds of formula I: wherein a, b, c, m, p, s, t, W, Ar 1 , X 1 , R 1 , R 2 , R 3 , R 4 , R 6 , and R 7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
1. A compound of formula I:
wherein:
a is 0 or 1;
each R 1 is halo;
b is 0 or an integer of from 1 to 2 4;
each R 2 is independently halo;
m is 0 or 1;
R 4 is selected from hydrogen and, (1-4C)alkyl
s is 0, 1 or 2;
Ar 1 represents a phenylene group wherein the phenylene group is substituted with (R 5 ) q where q is 0 or an integer from 1 to 4 and each R 5 is selected independently from halo, hydroxy, (1-4C)alkyl and (1-4C)alkoxy;
t is 0, 1 or 2;
p is 0, 1 or 2;
each R 6 independently represents halo or OR 6a , where R 6a is hydrogen or;
and
X 1 is selected from (1-3C)alkylene, —C(O)(1-3C)alkylene, (1-3C)alkyleneC(O)—, —SO 2 —, —SO 2 (1-3C)alkylene and (1-3C)alkyleneSO 2 —; where the alkylene group in any X 1 is optionally substituted with 1 or 2 substituents independently selected from (1-4C)alkyl and —NR Xa R Xb ; wherein R Xa and R Xb are independently selected from hydrogen and (1-4alkyl);
R 7 is selected from hydrogen and (1-4C)alkyl;
wherein each alkyl in R 6a is optionally substituted with 1 to 5 fluoro substituents;
or a pharmaceutically acceptable salt or stereoisomer thereof.
2. The compound of claim 1 , wherein a, and b each represent 0.
3. The compound of claim 1 , wherein a is 0, and b is 1.
4. The compound of claim 1 , wherein a is 1 and b is 2.
5. The compound of claim 1 , wherein m is 0 and t is 1
6. The compound of claim 1 , wherein Ar 1 represents phen-1,3-ylene, or phen-1,4-ylene.
7. The compound of claim 6 wherein q is 1 and R 5 is hydroxy.
8. The compound of claim 1 , wherein X 1 is selected from —CH 2 —, —CH 2 CH 2 — and —CH 2 C(O)—.
9. The compound of any one of claims 1 - 3 , 4 , or 5 - 8 wherein R 4 is hydrogen or methyl.
10. The compound of any one of claims 1 - 3 , wherein R 7 is hydrogen or methyl.
11. A compound selected from:
biphenyl-2-ylcarbamic acid 1-(2-{4-[(4-hydroxybenzylamino)methyl]phenylcarbamoyl}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-(4-{[2-(4-hydroxyphenyl)ethylamino]methyl}phenylcarbamoyl)ethyl]piperidin-4-yl ester;
(6-bromobiphenyl-2-yl)carbamic acid 1-(2-{4-[(3,5-dibromo-4-hydroxybenzylamino)methyl]phenylcarbamoyl}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{4-[(3,5-dibromo-4-hydroxybenzylamino) methyl]phenylcarbamoyl}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-(4-{[(4-hydroxybenzyl)methylamino]methyl}phenylcarbamoyl)ethyl]piperidin-4-yl ester;
biphenyl-2-yl-carbamic acid 1-(2-{3-[(4-hydroxy-3-methoxybenzylamino) methyl]benzylcarbamoyl}ethyl)piperidin-4-yl ester;
(3-fluorobiphenyl-2-yl)carbamic acid 1-(2-{4-[(4-hydroxybenzylamino) methyl]phenylcarbamoyl}ethyl)piperidin-4-yl ester;
(3′-chloro-3,5-difluorobiphenyl-2-yl)carbamic acid 1-(2-{4-[(4-hydroxybenzylamino)methyl]phenylcarbamoyl}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-(2-{3-hydroxy-4-[(4-hydroxybenzylamino) methyl]phenylcarbamoyl}ethyl)piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-{2-[3-({[2-(3,4-dihydroxyphenyl)-2-oxoethyl]methylamino}methyl)benzylcarbamoyl]ethyl}piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-{2-[3-({[2-(3,4-dihydroxyphenyl)ethyl]methylamino}methyl)benzylcarbamoyl]ethyl}piperidin-4-yl ester;
biphenyl-2-ylcarbamic acid 1-[2-(3-{[2-(4-hydroxyphenyl)ethylamino]methyl}benzylcarbamoyl)ethyl]piperidin-4-yl ester; and
biphenyl-2-ylcarbamic acid 1-[2-(3-hydroxy-4-{[2-(4-hydroxyphenyl) ethylamino]methyl}phenylcarbamoyl)ethyl]piperidin-4-yl ester;
or a pharmaceutically acceptable salt or solvate thereof.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a a compound of claim 1 or 11 .